J.P. Morgan Healthcare Confab Live Blog: Day Two

 

SAN FRANCISCO (TheStreet) -- I'm alive! I survived Day One of the J.P. Morgan Healthcare Conference and a night of drinking. Happy to be back providing live coverage on Day Two, with featured presentations by Regeneron Pharma (REGN), Vertex Pharma (VRTX), Amgen (AMGN) and Opko Health (OPK).

Today's live blog will operate much like yesterday's. I will be posting news updates and analysis throughout the day, live from the presentation rooms and breakout (Q&A) sessions. You can also follow me on Twitter, my handle is @adamfeuerstein.

Your best bet is to check back into the live blog several times throughout the day. Feel free to ping me with questions and comments. I'll do my best to respond and keep the live blog as interactive as possible.

Here's my planned schedule for Tuesday, subject to change, of course. All times Eastern.

Regeneron 10:30 am
Alkermes (ALKS) 11 am
Vertex 11:30 am
Amgen 12:30 pm
Enanta Pharma (ENTA) 2 pm
Orexigen (OREX) 2:30 pm
Ariad Pharma (ARIA) 6 pm
Opko 7:30 pm

More drinking and eating 8 pm to ???


-- Reported by Adam Feuerstein in San Francisco.  

Follow Adam Feuerstein on Twitter.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

More from Investing

Quick Read: 3 Things for Investors to Know Before Wednesday's Trading Session

Quick Read: 3 Things for Investors to Know Before Wednesday's Trading Session

Replay: Jim Cramer on the Markets, Oil, General Electric, Zillow and Micron

Replay: Jim Cramer on the Markets, Oil, General Electric, Zillow and Micron

Pegasystems Founder Explains Why He Has One of the Hottest Tech Stocks Around

Pegasystems Founder Explains Why He Has One of the Hottest Tech Stocks Around

Adobe Isn't Just Going After Shopify With Its Latest Acquisition

Adobe Isn't Just Going After Shopify With Its Latest Acquisition

Experts Break Down GDPR Risks for Investors

Experts Break Down GDPR Risks for Investors